Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Schering-Plough Now in the Feds' Crosshairs
- Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
- Discussion threads 2008-07-10
- Is Merck Hanging Schering Out to Dry on Vytorin?
- Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-07-07
- Prescriptions for Cholesterol Drugs Rise with New Generics
- To: HEALTH/MEDICAL EDITORSContact: Susan Herold of Consumers Union, +1-202-462-6262, sherold@consumer.org WASHINGTON, Feb. 13 /PRNewswire-USNewswire/ -- Prescriptions for the cholesterol-lowering medicines known as statins rose by an average of 500,000 a month between October 2005 and December 2006, according to a new analysis by Consumers Union and Consumer Reports Best Buy...
- Research articles 2007-02-13
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
- Lipitor faces first big generic hurdle
- As employers look to cut prescription drug costs, some consumers are finding Lipitor, the world's most popular drug, harder and more expensive to get. The leading anti-cholesterol drug is under pressure as employers push for use of lower-cost generics. In June, No. 2 anti-cholesterol drug Zocor went generic, setting...
- Research articles 2006-07-10
- Zocor move muddles generics strategies.(usage of generic drugs)
- Byline: GLORIA GONZALEZ Pharmaceutical manufacturer Merck & Co.'s decision to offer pricing incentives to encourage insurers and pharmacy benefit managers to favor its brand-name drug Zocor over recently introduced generic versions has initiat Byline: GLORIA GONZALEZ Pharmaceutical manufacturer Merck &...
- Research articles 2006-07-10
- Cheaper Zocor throws generic market a curveball
- A recent policy change by Merck to offer greater discounts for its cholesterol-lowering drug Zocor has employers, pharmacy benefit managers and insurers faced with making a tough decision: Should they follow what has been general tradition to this point a A recent policy change by Merck to offer greater discounts...
- Research articles 2006-09-15
- New Analysis Finds Medicare, Taxpayers Could Save $8.2B a Year if Seniors Were Prescribed Generics for Cholesterol Reduction
- WASHINGTON, Jan. 11 /U.S. Newswire/ -- Potential savings of $8.2 billion could be achieved in 2007 if Medicare beneficiaries were prescribed effective, lower-cost generic statins to reduce cholesterol instead of higher-priced brands, according to a new analysis by Consumers Union and Consumer Reports Best Buy Drugs. The savings would...
- Research articles 2006-01-11
- Cheaper Zocor throws generic market a curveball
- A recent change in policy adopted by large pharmaceutical firm Merck to offer greater discounts for its cholesterol-lowering drug Zocor has given employer-clients, pharmacy benefit managers and insurers a tough benefit design decision: Should they stick w A recent change in policy adopted by large pharmaceutical firm Merck to offer...
- Research articles 2006-10-01
- Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor®
- JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Novartis' generic unit, Sandoz, Inc., has filed a complaint in the United States District Court for the District of Columbia, seeking approval of its generic ZocorR products in the face of an April 30, 2006 decision of the same...
- Research articles 2006-06-23
- Merck & Co. Inc. (Active Pharmaceutical Ingredient Watch).(to change label for Zocor)(Brief Article)
- MERCK & Co. Inc. has received FDA approval for changes to the label for its cholesterol-lowering drug Zocor ... MERCK & Co. Inc. has received FDA approval for changes to the label for its cholesterol-lowering drug Zocor simvastatin to recommend a 40mg starting dose...
- Research articles 2003-04-28
- Expiring drug patents provide opening to promote generics; Cost savings may be major.(News)
- Byline: GLORIA GONZALEZ The recent expiration of the patents on blockbuster prescription drugs Zocor and Zoloft represents a tremendous opportunity to reinvigorate generic drug promotion programs, insurers and pharmacy benefit managers say. The Byline: GLORIA GONZALEZ The...
- Research articles 2006-07-17
- Aetna Pharmacy Management to Launch a Generic First Program in Response to Zocor's Patent Expiring
- HARTFORD, Conn. -- Aetna (NYSE:AET) Pharmacy Management APM today announced it will encourage members to use generics first when the patent for Zocor expires this Friday. Aetna is supporting Teva Pharmaceuticals (NASDAQ:TEVA), which manufactures the generic alternative Simvastatin, to help provide customers with continued access to affordable, appropriate prescription drug...
- Research articles 2006-06-22
- Enhancing employee health
- What's for lunch today? Pizza and potato chips? Fish and salad? We love choices at mealtime, but many of us make poor ones by eating too many fatty foods. That's why millions of Americans have high cholesterol, a major risk factor for heart disease and st What's for lunch today?...
- Research articles 2006-06-01
- PFIZER INC - Research Update.
- Pfizer's Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures at an Overall Cost Savings Compared to Zocor, New...
- Research articles 2006-05-16
- Cholesterol-lowering treatment with Merck's Zocor shown to save lives, prevent heart attacks in elderly
- the landmark Scandinavian Simvastatin Survival Study (4S) demonstrate that treating elderly patients who have heart disease and high cholesterol with ZocorR simvastatin reduced death due to heart disease by 43 percent and reduced death from any cause by 34 percent.
- Research articles 1995-11-15
- Merck & Co. Inc. (Active Pharmaceutical Ingredient Watch).(alters Zocor label)(Brief Article)
- MERCK & Co. Inc. reports that changes to the existing label for cholesterol-lowering drug Zocor simvastatin further clarify the risk of myopathy and rhabdomyolysis, particularly with higher doses and when used with certain drugs. Merck reques MERCK & Co. Inc. reports that changes to...
- Research articles 2002-06-17
- Forbes Medi-Tech Preclinical Study Results Demonstrate Cholesterol-Lowering Effects of FM-VP4/Statin 'Zocor' Combination and Effects on Obesity
- VANCOUVER, British Columbia -- Forbes Medi-Tech Inc. (NASDAQ:FMTI)(TSX:FMI) today announced the results from two pre-clinical studies involving the Company's cholesterol-lowering drug, FM-VP4. The first study was designed to assess the effects of Forbes' cholesterol-lowering drug candidate, FM-VP4, in combination with Simvastatin ZocorRi from Merck (NYSE:MRK),...
- Research articles 2005-09-15
- Ranbaxy gets taste of Merck bestseller.
- May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva Pharmaceutical are likely to get a windfall by having six months without competition to sell their generic versions of Merck's blockbuster cholesterol drug Zocor. May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva...
- Research articles 2006-05-03
- MERCK & CO. Inc.'s.
- MERCK & CO. Inc.'s Zocor simvastatin, a cholesterol-lowering drug, has received FDA approval ... MERCK & CO. Inc.'s Zocor simvastatin, a cholesterol-lowering drug, has received FDA approval as the first cholesterol-modifying drug indicated to increase HDL cholesterol, or good cholesterol.
- Research articles 1999-08-23
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
